Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
VANRY (VANRY) 41.2% amplitude in 24 hours: Trading volume surge drives speculative volatility

VANRY (VANRY) 41.2% amplitude in 24 hours: Trading volume surge drives speculative volatility

Bitget PulseBitget Pulse2026/03/16 21:02
Show original
By:Bitget Pulse

Volatility Overview

In the past 24 hours, VANRY's price touched a low of $0.00507 and a high of $0.00716, currently quoted at $0.0066, reflecting a price fluctuation of 41.2%. The 24-hour trading volume surged significantly to approximately $94.71 million (CoinMarketCap data), with futures trading volume exceeding $13.58 million (CoinGlass data), far above the current market cap of about $12 million, indicating high market activity.

Brief Analysis of Unusual Movements

• Explosive surge in trading volume: 24-hour spot trading volume reached $74.63 million–$94.71 million, with futures volume exceeding $13.58 million—over seven times the market cap—triggering high-frequency speculative trading and intense price swings.

• No official announcement, major news, or on-chain whale transfers within 24 hours have been reported (no abnormal activity detected on CryptoQuant and X monitoring).

• Community technical discussions are active. For example, analysts on X have highlighted that the 4-hour chart broke out of a falling wedge pattern, supporting the recent rebound.

Market View and Outlook

Mainstream sentiment in the community is bullish. Multiple analysts on X, such as Finora AI and Whales_Crypto_Trading, are optimistic about short-term upside, suggesting attention to long entry opportunities near $0.00495, targeting $0.0053–$0.006. However, they warn that if $0.00476 is lost, the trend turns bearish, with risk of retesting lower support levels.

Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, and is for informational purposes only.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify

In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.

华尔街见闻•2026/11/06 15:01

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23